Summary
BeOne Medicines Ltd. (ONC) announced a significant change in its clinical development strategy for pamiparib, a PARP inhibitor. The company is converting its ongoing Phase 3 trial (BGB-290-303) in gastric cancer patients from Phase 3 to Phase 2. This decision was prompted by slower-than-expected patient enrollment globally since the trial began in July 2018. It is important for investors to note that the company explicitly stated this change is not due to any safety or efficacy concerns with pamiparib. The company intends to leverage the data generated from the Phase 2 portion to further evaluate pamiparib's potential in this specific indication. Future development plans will be determined based on these findings, including potential strategies for monotherapy or combination treatments. This strategic shift reflects a pragmatic approach to data evaluation and resource allocation in the development of pamiparib.
Key Highlights
- 1BeOne Medicines is converting its Phase 3 trial of pamiparib for gastric cancer from Phase 3 to Phase 2.
- 2The trial (NCT 03427814) focuses on pamiparib as maintenance therapy in patients with inoperable locally advanced or metastatic gastric cancer.
- 3The decision is attributed to slower-than-expected patient enrollment globally.
- 4The company emphasizes that the change is NOT due to safety or efficacy issues.
- 5Data from the Phase 2 trial will be used to assess pamiparib's potential and inform future development steps.
- 6Future development may include monotherapy or combination therapy approaches.
- 7The announcement was made at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI).